Comparative Efficacy of NASO B12 Versus Sublingual Methylcobalamin in Treating Vitamin B12 Deficiency: A Randomised Open-Label Clinical Trial

Background: Vitamin B12 is crucial for DNA synthesis, haematological and neurological functions. Conventional Vitamin B12 supplementation methods, including intramuscular and oral routes, have limitations. The intramuscular injections are painful, and their dosing schedule is inconvenient. Methylcobalamin oral tablets lack consistent and predictable absorption of vitamin B12. NASO B12 (Methylcobalamin nasal spray) offers a painless and novel alternative; however, there is no data to compare it directly with Methylcobalamin sublingual tablets. Objective: To evaluate the efficacy of NASO B12 (Methylcobalamin 250 mcg/spray) versus Methylcobalamin sublingual tablet (1500 mcg) in Vitamin B12-deficient patients. Methods: In a randomised, open-label study conducted at a primary healthcare facility, 30 patients with confirmed Vitamin B12 deficiency (<200 pg/ml) were administered either NASO B12 (500 mcg every alternate day) or Methylcobalamin sublingual tablet available on the market (1500 mcg every alternate day). Vitamin B12 levels in the blood were measured at baseline, 30 minutes after administration of the first dose, and on Day 6 (a total of three doses of each product). Results: NASO B12 achieved significantly higher Vitamin B12 levels in the blood, 30 minutes after administration of first dose (1397.3 ± 369.03 pg/ml vs. 197.9 ± 29.7 pg/ml, p < 0.001) and on Day 6 (839.5 ± 163.02 pg/ml vs. 267.6 ± 37.61 pg/ml, p < 0.001). NASO B12 showed a greater mean increase in serum Vitamin B12 levels from baseline than the sublingual tablet at both 30 minutes (1,219.7 vs. 24.7 pg/mL) and Day 6 (661.8 vs. 94.4 pg/mL). All patients in the NASO B12 group achieved a Vitamin B12 ≥ 400 pg/ml level as recommended by the American Academy of Family Physicians (AAFP), whereas none of the patients in the Methylcobalamin sublingual tablet group achieved the same. Both treatments were well tolerated. Conclusion: NASO B12 exhibited rapid, predictable and superior absorption, along with sustained therapeutic Vitamin B12 levels (>400 pg/ml), as compared to the Methylcobalamin sublingual tablet. This highlights the potential of NASO B12 as an effective and patient-friendly alternative for the rapid and assured correction of Vitamin B12 deficiency.

Authors

Institutions

Publication Details

Journal
International Blood Research & Reviews
Published
2025-05-28
DOI
https://doi.org/10.9734/ibrr/2025/v16i1352
Primary Topic
Folate and B Vitamins Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Comparative Efficacy of NASO B12 Versus Sublingual Methylcobalamin in Treating Vitamin B12 Deficiency: A Randomised Open-Label Clinical Trial

Banshi Saboo
International Blood Research & Reviews
Folate and B Vitamins Research
article

Comparative Efficacy of NASO B12 Versus Sublingual Methylcobalamin in Treating Vitamin B12 Deficiency: A Randomised Open-Label Clinical Trial

Banshi Saboo
article en

Abstract

Background: Vitamin B12 is crucial for DNA synthesis, haematological and neurological functions. Conventional Vitamin B12 supplementation methods, including intramuscular and oral routes, have limitations. The intramuscular injections are painful, and their dosing schedule is inconvenient. Methylcobalamin oral tablets lack consistent and predictable absorption of vitamin B12. NASO B12 (Methylcobalamin nasal spray) offers a painless and novel alternative; however, there is no data to compare it directly with Methylcobalamin sublingual tablets. Objective: To evaluate the efficacy of NASO B12 (Methylcobalamin 250 mcg/spray) versus Methylcobalamin sublingual tablet (1500 mcg) in Vitamin B12-deficient patients. Methods: In a randomised, open-label study conducted at a primary healthcare facility, 30 patients with confirmed Vitamin B12 deficiency (<200 pg/ml) were administered either NASO B12 (500 mcg every alternate day) or Methylcobalamin sublingual tablet available on the market (1500 mcg every alternate day). Vitamin B12 levels in the blood were measured at baseline, 30 minutes after administration of the first dose, and on Day 6 (a total of three doses of each product). Results: NASO B12 achieved significantly higher Vitamin B12 levels in the blood, 30 minutes after administration of first dose (1397.3 ± 369.03 pg/ml vs. 197.9 ± 29.7 pg/ml, p < 0.001) and on Day 6 (839.5 ± 163.02 pg/ml vs. 267.6 ± 37.61 pg/ml, p < 0.001). NASO B12 showed a greater mean increase in serum Vitamin B12 levels from baseline than the sublingual tablet at both 30 minutes (1,219.7 vs. 24.7 pg/mL) and Day 6 (661.8 vs. 94.4 pg/mL). All patients in the NASO B12 group achieved a Vitamin B12 ≥ 400 pg/ml level as recommended by the American Academy of Family Physicians (AAFP), whereas none of the patients in the Methylcobalamin sublingual tablet group achieved the same. Both treatments were well tolerated. Conclusion: NASO B12 exhibited rapid, predictable and superior absorption, along with sustained therapeutic Vitamin B12 levels (>400 pg/ml), as compared to the Methylcobalamin sublingual tablet. This highlights the potential of NASO B12 as an effective and patient-friendly alternative for the rapid and assured correction of Vitamin B12 deficiency.

International Blood Research & ReviewsVol. 16(1)
Diabetes Care & Hormone Clinic (IN)
Openalex Percentile: Top 81%
Folate and B Vitamins Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.